Interferon-beta exposure in-utero and the risk of infections in early childhood
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Interferon-beta exposure in-utero and the risk of infections in early childhood. / Windfeld-Mathiasen, Josefine; Horwitz, Henrik; Andersen, Johanna Balslev; Framke, Elisabeth; Gade, Christina; Andersen, Jon Trærup; Magyari, Melinda.
In: Multiple Sclerosis and Related Disorders, Vol. 77, 104867, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Interferon-beta exposure in-utero and the risk of infections in early childhood
AU - Windfeld-Mathiasen, Josefine
AU - Horwitz, Henrik
AU - Andersen, Johanna Balslev
AU - Framke, Elisabeth
AU - Gade, Christina
AU - Andersen, Jon Trærup
AU - Magyari, Melinda
N1 - Publisher Copyright: © 2023
PY - 2023
Y1 - 2023
N2 - Background: Knowledge within the field of multiple sclerosis treatment during pregnancy is vital to ensure the most optimal clinical practice. Immunomodulatory treatment in pregnancy could in theory affect the normal development and maturation of the immune system of the fetus with a potential increased risk of infections, consequently. We therefore set out to investigate whether exposure to interferon-beta in utero affected the risk of acquiring infections in early childhood. Methods: This retrospective matched cohort study utilized data from the Danish Multiple Sclerosis Registry linked with national Danish registries to identify all children born of mothers with MS in Denmark from 1998 to 2018. The study included 510 children exposed to interferon-beta in utero. The children were matched 1:1 on various of demographic characteristics with children born to mothers with untreated MS and 1:3 with children born to mothers without MS. Each child was followed for up to five years. Using individual-level data, we investigated all-cause mortality, rate of hospital admissions due to infections, and redeemed prescriptions of antibiotics. The primary statistical model applied was a negative binomial regression analysis. Results: We found no differences in childhood mortality, for hospital admissions the rate ratio compared to healthy controls was 0.79 (0.62–1.00). Regarding antibiotic prescriptions, the results were similar (RR 1.00 (0.90–1.11). Furthermore, we found no certain dose-response relationship between interferon-beta exposure duration and hospital admission rate (P = 0.47) or redeemed antibiotic prescription (P = 0.71). Conclusion: Exposure to interferon-beta during gestation has little to no impact on the risk of acquiring significant infections during the first five years of childhood.
AB - Background: Knowledge within the field of multiple sclerosis treatment during pregnancy is vital to ensure the most optimal clinical practice. Immunomodulatory treatment in pregnancy could in theory affect the normal development and maturation of the immune system of the fetus with a potential increased risk of infections, consequently. We therefore set out to investigate whether exposure to interferon-beta in utero affected the risk of acquiring infections in early childhood. Methods: This retrospective matched cohort study utilized data from the Danish Multiple Sclerosis Registry linked with national Danish registries to identify all children born of mothers with MS in Denmark from 1998 to 2018. The study included 510 children exposed to interferon-beta in utero. The children were matched 1:1 on various of demographic characteristics with children born to mothers with untreated MS and 1:3 with children born to mothers without MS. Each child was followed for up to five years. Using individual-level data, we investigated all-cause mortality, rate of hospital admissions due to infections, and redeemed prescriptions of antibiotics. The primary statistical model applied was a negative binomial regression analysis. Results: We found no differences in childhood mortality, for hospital admissions the rate ratio compared to healthy controls was 0.79 (0.62–1.00). Regarding antibiotic prescriptions, the results were similar (RR 1.00 (0.90–1.11). Furthermore, we found no certain dose-response relationship between interferon-beta exposure duration and hospital admission rate (P = 0.47) or redeemed antibiotic prescription (P = 0.71). Conclusion: Exposure to interferon-beta during gestation has little to no impact on the risk of acquiring significant infections during the first five years of childhood.
KW - Drug exposure
KW - Fetotoxicity
KW - Immunology
KW - Interferon-beta
KW - Multiple sclerosis
KW - Pregnancy
U2 - 10.1016/j.msard.2023.104867
DO - 10.1016/j.msard.2023.104867
M3 - Journal article
C2 - 37423048
AN - SCOPUS:85165244765
VL - 77
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
SN - 2211-0348
M1 - 104867
ER -
ID: 366767368